Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Blank, Susanne; Schmidt, Thomas; Heger, Patrick; Strowitzki, Moritz J.; Sisic, Leila; Heger, Ulrike; Nienhueser, Henrik; Haag, Georg Martin; Brückner, Thomas; Mihaljevic, André L.; Ott, Katja; Büchler, Markus W.; Ulrich, Alexis

doi:10.1007/s10120-017-0746-1

Cited by 81 publications

(99 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have shown no oncological benefit between esophagectomy and gastrectomy. 12 A retrospective study by Blank et al 13 compared 56 patients undergoing esophagogastrecomy, with 186 patients treated by transhiatal extended gastrectomy. The results showed no significant difference in R0 resection rates and number of resected lymph nodes, though a better survival in the Ivor-Lewis group.…”

Section: Surgical Treatmentmentioning

confidence: 99%

Cancer of the gastroesophageal junction: a diagnosis, classification, and management review

Chevallay

Bollschweiler

Chandramohan

et al. 2018

Annals of the New York Academy of Sciences

Self Cite

View full text Add to dashboard Cite

Management of gastroesophageal junction (GEJ) adenocarcinoma is a controversial topic. The rising incidence of this cancer requires a clear consensus to ensure proper management. Application of oncological principles for tumors of the esophagus or stomach is not possible because of comparative differences in the biology of GEJ adenocarcinoma, leading to different therapeutic options. Staging work-up with endoscopy, endosonography, and PET is essential to inform the choice of neoadjuvant treatment and surgical approach to GEJ adenocarcinoma. Surgery remains the only curative treatment and should be undertaken in specialized centers.

show abstract

Section: Surgical Treatmentmentioning

confidence: 99%

Cancer of the gastroesophageal junction: a diagnosis, classification, and management review

Chevallay

Bollschweiler

Chandramohan

et al. 2018

Annals of the New York Academy of Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that residual cancer is closely related to the surgical approach. 18,19 In our study, four cases of upper margin cancer residue were detected using the abdominal approach and three from the thoracic approach, indicating that the cancer residue margin was related to surgical approach. Tumor invasion depth was closely related to prognosis and five-year survival rate sin patients with EGJA.…”

Section: Discussionmentioning

confidence: 57%

Short‐term postoperative complications and prognostic factors in patients with adenocarcinoma of the esophagogastric junction

Zhang

Peng

2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe study was conducted to investigate the short‐term complications and prognostic factors in patients with esophagogastric junction adenocarcinoma (EGJA).MethodsThis retrospective study included 110 EGJA patients who underwent surgery from January 2010 to November 2012 at The First Affiliated Hospital of BengBu Medical College. The overall survival and short‐term complications were analyzed according to the patients’ clinical characteristics.ResultsThe incidence of postoperative cardiopulmonary complications was significantly higher in patients with preoperative cardiopulmonary disease or elderly patients (P < 0.05). Four cases of upper margin cancer residue were detected using the abdominal approach and three using the thoracic approach, which indicated that the cancer residue margin was related to surgical approach. The overall five‐year survival rate was 34.3% and statistically differed according to pathological stage and en block resection (P all < 0.05). Cox regression analysis showed that lymph node metastasis (P < 0.05) and the extent of tumor invasion (P < 0.05) were independent prognostic factors.ConclusionElderly patients with preoperative cardiopulmonary disease had an increased risk of developing postoperative cardiopulmonary complications. Lymph node status and depth of tumor invasion were independent factors related to patient prognosis.

show abstract

“…And the number of resected lymph node and rate of R0 resection have no difference as well. Overall survival after TAE was significantly longer than after THG (33.6 months vs. not reached, P = 0.02) [13] . It suggested TAE isn't worse than THG for Siewert type II AEG, especially for advanced patients who had neoadjuvant chemotherapy.…”

Section: Optimal Surgical Approach For Siewert Type II Aegmentioning

confidence: 88%

Siewert type II adenocarcinoma of esophagogastric junction: treatment status

Li¹,

Zang²

2019

MIS

View full text Add to dashboard Cite

The incidence of adenocarcinoma of esophagogastric junction (AEG) has been increased continuously in the past decades, especially in western countries. Siewert type II is regard as the true AEG because of its location, however, the treatment for Siewert type II AEG has not reached a consensus in the academic. According to published studies nowadays, this commentary will introduce the surgical strategies and put forward suggestions for Siewert type II AEG in several aspects as follows: (1) optimal surgical approach; (2) optimal extent of lymph node dissection; (3) reconstruction methods. With the development of minimally invasive surgery, many experienced surgeons perform esophagogastrostomy via transhiatal approach. Moreover, many details during the surgery still need further research by cooperation between different departments and even countries.

show abstract

Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Cited by 81 publications

References 51 publications

Cancer of the gastroesophageal junction: a diagnosis, classification, and management review

Cancer of the gastroesophageal junction: a diagnosis, classification, and management review

Short‐term postoperative complications and prognostic factors in patients with adenocarcinoma of the esophagogastric junction

Siewert type II adenocarcinoma of esophagogastric junction: treatment status

Contact Info

Product

Resources

About